Current developments, limitations and future directions of CAR T-cell therapy

Abstract

Since CAR T-cell therapies were authorized for clinical use in 2017, it has demonstrated massive potential in treating hematological malignancies, with more than 750 active CAR T-cell therapies currently under development around the world. However, despite the successes, many side effects and limitations still remain for this relatively new cancer treatment which is preventing the more extensive usage of this therapy. Thus, more innovative solutions must be established to eliminate or reduce the issues regarding the therapy. This paper will review some of the past and current developments of CAR T-cell therapy, some issues, limitations and its effect on the efficacy of the treatment as well as some of the novel methods and future directions which can be utilized to reduce or eliminate many of the limitations.